ResMed Inc. (RMD) Set to Announce Quarterly Earnings on Tuesday

ResMed Inc. (NYSE:RMD) is scheduled to announce its earnings results after the market closes on Tuesday, August 1st. Analysts expect the company to announce earnings of $0.75 per share for the quarter.

ResMed (NYSE:RMD) last released its earnings results on Thursday, April 27th. The medical equipment provider reported $0.71 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.70 by $0.01. The company had revenue of $514.20 million during the quarter, compared to analyst estimates of $525.84 million. ResMed had a net margin of 15.96% and a return on equity of 22.53%. The firm’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.68 EPS. On average, analysts expect ResMed to post $2.8 EPS for the current fiscal year and $3.12 EPS for the next fiscal year.

Shares of ResMed Inc. (NYSE:RMD) opened at 77.39 on Friday. The company has a 50-day moving average of $77.07 and a 200 day moving average of $71.57. ResMed Inc. has a 12-month low of $56.59 and a 12-month high of $79.63. The stock has a market capitalization of $10.98 billion, a price-to-earnings ratio of 33.94 and a beta of 0.84.

ILLEGAL ACTIVITY WARNING: “ResMed Inc. (RMD) Set to Announce Quarterly Earnings on Tuesday” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/07/30/resmed-inc-rmd-set-to-announce-quarterly-earnings-on-tuesday.html.

Several research analysts recently weighed in on RMD shares. J P Morgan Chase & Co cut ResMed from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $72.00 to $71.00 in a research report on Thursday, April 20th. Zacks Investment Research upgraded ResMed from a “sell” rating to a “hold” rating in a research report on Wednesday, April 12th. William Blair reiterated an “outperform” rating on shares of ResMed in a research report on Thursday, April 13th. BMO Capital Markets reiterated a “hold” rating on shares of ResMed in a research report on Friday, May 12th. Finally, Citigroup Inc. cut ResMed from a “buy” rating to a “neutral” rating in a research report on Friday, April 28th. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $64.50.

In other news, insider James Hollingshead sold 7,140 shares of the business’s stock in a transaction that occurred on Friday, July 14th. The stock was sold at an average price of $77.43, for a total value of $552,850.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jr. Gregor K. Emmert acquired 424,000 shares of the business’s stock in a transaction dated Wednesday, June 28th. The stock was acquired at an average price of $0.06 per share, with a total value of $25,440.00. Insiders sold 180,261 shares of company stock valued at $13,560,373 over the last 90 days. Company insiders own 1.97% of the company’s stock.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Earnings History for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply